Pancreatic cancer – current effective diagnostic and therapeutic approach
Authors:
prof. MUDr. CSc. Miroslav Ryska
Authors‘ workplace:
Chirurgická klinika 2. LF UK a ÚVN Praha: U vojenské nemocnice 1200, Praha
Fakulta zdravotnictva a sociální práce, Trnavská univerzita, Trnava
6
Published in:
Čas. Lék. čes. 2016; 155: 38-43
Category:
Review Articles
Overview
Pancreatic cancer is solid malignant, chemoresistant tumour with unfavourable prognosis. Radical resection with adjuvant chemotherapy is only potential curable therapeutic modality enabling to prolong survival of 20 % patients. Borderline conception contents active approach to primary non-resectable patients to reach resectability by neoadjuvant chemo(radio)therapy. Palliative and symptomatic therapy is indicated in about 70 % patients.
In the case of suspicious of pancreatic cancer, patient should be referral to specialized centre. Effective diagnostic therapeutic approach only guarantees optimal quality of life of these patients.
Key words:
pancreatic cancer – diagnosis and therapy, multidisciplinary approach, quality of life
Sources
1. Dušek L, Kubásek M, Koptíková J et al. Epidemiologie zhoubných nádorů v České republice. Dostupné na: http://www.svod.cz
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605–1617.
3. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
4. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19: F9–F26.
5. Frebourg T, Bercoff E, Manchon N et al. The evaluation of Ca 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287–2290.
6. Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy gemcitabine and long-term outcomes among patients with resected pancreaticcancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473–1481.
7. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013; 24: 2484–2492.
8. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114–1117.
9. Cooper M, Newman NA, Ibrahim AM et al. Unnecessary tests and procedures in patients presenting with solid tumors of the pancreas. J Gastrointest Surg 2013; 17: 1218–1223.
10. Ryska M, Dušek L, Pohnán R et al. Kvalita života je důležitým faktorem indikační rozvahy u nemocných s karcinomem pankreatu. Multicentrická prospektivní studie. Rozhl Chir 2012; 91: 207–216.
11. Ducreux M, Cuhna AS, Caramella V et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: v56–v68.
12. Pietryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol 2015; 6: 343–357.
13. Ardengh JC, Malheiros CA, Pereira V et al. Endoscopic ultrasound-guided fine-needle aspiration using helical computerized tomography for TN staging and vascular injury in operable pancreatic carcinoma. JOP 2009; 10: 310–317.
14. Petr WT, Pistes MD, Wayne A et al. Effect of praeoperative biliary decompression on pancreaticoduodenectomy – associated morbidity in 300 consecutive patients. Ann Surg 2001; 234: 47–55.
15. Tempero, MA, Arnoletti JP, Behrman SW et al. Pancreatic adenocarcinoma, vision 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 703–713.
16. Glanemann M, Shi B, Liang F et al. Surgical strategies for treatment of malignit pancreatic tumors: extended, standard or local surgery? World J Surg Oncol 2008; 6: 123.
17. Nimura Y, Nagino M, Takao S et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012; 19: 230–241.
18. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the word. HPB 2008; 10: 58–62.
19. Büchler MW, Wagner M, Schmied BM et al. Changes in morbidity after pancreatic resection. Toward the end of completion pancreatectomy. Arch Surg 2003; 138: 1210–1314.
20. Faccioli N, Foti G, Molinari E et al. Role of fistulography in evaluating pancreatic fistula after pancreaticoduodenectomy. BJR 2012; 85: 219–224.
21. Gerritsen A, Wennink RAW, Besselink MGH et al. Early oral feeding after pancreatoduodenectomy enhances recovery without increasing morbidity. HPB 2014; 16: 656–664.
22. Katz MH, Marsh R, Herman JM et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787–2795.
23. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. WJG 2014; 20: 10740–10751.
24. Katz MH, Fleming JB, Bhosale P et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012; 118: 5749–5756.
25. Nentwich MF, König A, Izbicki JR. Limit of surgery for pancreatic cancer. Rozhl Chir 2014; 93: 445–449.
26. Chuong MD, Springett GM, Freilich JM et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013; 86: 516–522.
27. Barugola G, Partelli S, Crippa S et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012; 203: 132–139.
28. Chauffert B et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5‑FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann Oncol 2008; 19: 1592–1599.
29. Ohuchida K et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor–stromal interactions. Cancer Res 2004; 64: 3215–3222.
30. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073–1081.
31. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141: 610–618.
32. Rochefort MM, Ankeny JS, Kadera BE et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol 2013; 20: 4322–4329.
33. Verbeke CS, Leitch D, Menon KV et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006; 93: 1232–1237.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Pancreatic cancer – current effective diagnostic and therapeutic approach
- Malignant biliary obstruction
- Professor Josef Marek - octogenarian
- Foregut diseases: foregut neoplasms